Usability of Hematologic Parameters in Primary Care to Show Disease Activity in Patients with Ankylosing Spondylitis

Öz

Introduction: Ankylosing spondylitis (AS) is a type of chronic inflammatory arthritis resulting in ankylosis of the spine and inflammation of the tendons. In this study, we aimed to investigate the usability of hematologic parameters to determine disease activity in AS patients. Materials and Methods: A total of 65 patients who were previously diagnosed with AS were enrolled retrospectively in the current study. Patients were divided into two groups according to their Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores. Thirty-one patients who had BASDAI score > 5 served as “active AS” and 34 patients who had BASDAI score < 5 served as “inactive AS”. Patients data including their physical examination findings were recorded. Medications, demographic properties, and laboratory findings of the patients were also recorded. Results: The clinical and demographic features of both groups were comparable. There were no differences between groups according to the use of medications, the duration of AS and the presence of uveitis, enthesopathy, and peripheral arthritis. In laboratory findings, the Erythrocyte Sedimentation Rate (ESR), C-reactive Protein (CRP) and Neutrophil/Lymphocyte Ratio (NLR) were significantly higher, Mean Platelet Volume (MPV) was significantly lower in active AS group than in inactive AS group. In the correlation analysis, BASDAI score had a significantly negative correlation with MPV (r=-0.309, p=0.012) and significantly positive correlations with ESR, CRP and N/L values (r=0.427, p<0.001, r=0.328, p=0.008 and r=0.316, p=0.010, respectively). In linear regression analysis , only MPV score was found to be a predictor for AS activity (p<0.04).Conclusion: Mean platelet volume is significantly negative correlated with BASDAI score and could provide a clue for primary care physician which patients who are at high risk for AS activity. Giriş: Ankilozan spondilit (AS) omurgada ankiloza yol açan ve tendonlarda inflamasyon oluşturan kronik inflamatuvar artrit çeşididir. Bu çalışmada, AS hastalarında hastalık aktivitesini göstermede hematolojik parametrelerin kullanılabilirliğini araştırdık. Gereç ve Yöntem: Çalışmaya daha önce AS tanısıyla takip edilen toplam 65 hasta retrospektif olarak dahil edildi. Hastalık aktivitesini gösteren Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) skoruna göre hastalar iki gruba ayrıldı. BASDAI skoru> 5 olan toplam 31 hasta aktif AS ve BASDAI skoru < 5 olan toplam 34 hasta inaktif AS olarak ayrıldı. Detaylı fizik muayene bulguları da olmak üzere tüm hastaların verileri kaydedildi. Ayrıca hastaların ilaç kullanımları, demografik ve laboratuvar verileri kaydedildi. Bulgular: Her iki grup klinik ve demografik özellikler açısından benzerdi. Ayrıca ilaç kullanım öyküsü, hastalık yaşı, üveit varlığı, entesopati varlığı ve periferik artrit varlığı açısından da iki grup arasında istatiksel fark saptanmadı. Aktif AS grubunda Eritrosit Sedimentasyon Hızı (ESH), C-reaktif Protein (CRP) ve Nötrofil/Lenfosit oranı (NLR) inaktif AS grubuna göre belirgin olarak yüksek, Ortalama Platelet Hacmi (OPH) ise belirgin olarak düşük saptandı. Korelasyon analizinde BASDAI skoru OPH ile belirgin negatif (r=-0,309, p=0,012), ESH, CRP ve NLR ile belirgin pozitif korelasyona sahipti (sırasıyla, r=0,427, p<0,001, r=0,328, p=0,008 ve r=0,316, p=0,010). Bu değişkenler lineer regresyon analizine sokulduğunda sadece OPH’ nin AS hastalık aktivitesini predikte ettiği saptandı (p<0,04). Sonuç: OPH hastalık aktivitesini gösteren BASDAI skoru ile belirgin şekilde negatif ilişkilidir ve birinci basamak aile hekimleri için hangi hastaların AS aktivitesi için yüksek riskli olduğuna dair bir ipucu sağlayabilir.

Anahtar Kelimeler

• Ankylosing spondylitis,BASDAI score,neutrophyl/lymphocyte ratio,mean platelet volume,primary care

Kaynakça

1. 1. El Maghraoui A. Extra-articularmanifestations of ankylosingspondylitis: prevalence, characteristics and therapeuticimplications. Eur J InternMed 2011; 22:554-60.
2. 2. Zochling J, Braun J. Mortality in rheumatoid arthritis and ankylosing spondylitis. ClinExpRheumatol 2009;27:127–130.
3. 3. Boyraz I, Koç B, Boyacı A, Tutoğlu A, Sarman H, Ozkan H. Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that aretreating with anti-TNF. Int J ClinExpMed 2014; 7:2912-5.
4. 4. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21(12): 228691.
5. 5. Torun S, TuncBD, Suvak B, et al. Assessment of neutrophil lymphocyte ratio in ulcerative colitis: A promising marker in predicting disease severity. ClinResHepatolGastroenterol 2012;36(5):491–497.
6. 6. TamhaneUU, Aneja S, Montgomery D, Rogers EK, EagleKA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008;102(6):653–657. 19.
7. 7. Gupta N, Saigal R, Goyal L, Agrawal A, Bhargava R, Agrawal A. Carotid intima media thickness as a marker of atherosclerosis in ankylosing spondylitis.Int J Rheumatol. 2014;2014:839135. doi: 10.1155/2014/839135.
8. 8. Boyraz I, Onur Caglar S, Erdem F, Yazici M, Yazici S, Koc B, Gunduz R, Karakoyun A. Assessment of relation between neutrophil lympocyte, platelet lympocyte ratio sandepicardial fatthickness in patients with ankylosing spondylitis. MedGlas (Zenica). 2016 Feb 1;13(1):14-7. doi: 10.17392/832-16.

9. 9. Kocer D, Sarıgüzel FM, Güler E, Karakükcü Ç, Sütbeyaz ST, Gödekmerda A. MPV Değerinin AnkilozanSpondilitli Hastalarda Enflamasyon Belirteci Olarak Değerlendirilmesi. Türk Klinik Biyokimya Derg 2014; 12(2): 73-77.
10. 10. Kantola T, Klintrup K, VayrynenJP, et al. Stage-dependentalterations of the serum cytokinepattern in colorectalcarcinoma. Br J Cancer 2012;107(10):1729–1736.
11. 11. Cascao R, RosarioHS, Souto-Carneiro MM, Fonseca JE. Neutrophils in rheumatoidarthritis: Morethansimplefinaleffectors. AutoimmunRev 2010;9(8):531–535.
12. 12. SherlockJP, Buckley CD, CuaDJ. Thecritical role of interleukin23 in spondylo arthropathy.MolImmunol 2014;57(1):38–43.
13. 13. MorrellCN, Aggrey AA, ChapmanLM, ModjeskiKL. Emerging roles for platelets as immune and inflammatorycells. Blood. 2014; 123: 2759–2767. https://doi.org/10.1182/blood-2013-11-462432 PMID: 24585776; PubMed Central PMCID: PMCPMC4007605.
14. 14. SempleJW, Italiano JE Jr, Freedman J. Platelet sandtheimmunecontinuum. NatRevImmunol. 2011; 11: 264–274. https://doi.org/10.1038/nri2956 PMID: 21436837.
15. 15. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, OzturkM.A, et al. Meanplatelet volüme (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoidarthritis. Joint Bone Spine 2008; 75(3): 291-294.
16. 16. Gasparyan AY, Sandoo A, Kalinoglou AS, Kitas GD. Mean platelet volume in patients with rheumatoid arthritis: theeffect of anti-TNF-alphatherapy. RheumatolInt 2010; 30(8): 1125–1129.
17. 17. Bath PM, ButterworthRJ. Platelet size: measurement, physiologyandvasculardisease. Blood CoagulFibrinolysis 1996; 7(2): 157-61.
18. 18. BerteroMT, Caligaris-Cappio F. Anemia of chronicdisorders in systemic autoimmune diseases. Haematologica 1997; 82(3): 375-81.
19. 19. Ertenli I, Kiraz S, OzturkMA, Haznedaroğlu IC, Celik I, Calgüneri M. Pathologic thrombopoiesis of rheumatoidarthritis. RheumatolInt 2003(2); 23: 49-60.
20. 20. Nishimoto N. Interleukin-6 in rheumatoid arthritis. CurrOpinRheumatol 2006; 18(3): 277-81.
21. 21. ThompsonCB. From precursortoproduct: how do megakaryocytes produce platelets? ProgClinBiolRes 1986; 215: 361-71.
22. 22. ThompsonCB, JakubowskiJA. The pathophysiology and clinical relevance of platelet heterogeneity. Blood 1988; 72: 1-8.